Follow ExThera Medical at www.Healthios/Xchange.com “Each year there are 1.8 million new cases of bloodstream infection in the U.S. and Europe, causing patients serious complications and imposing a high cost burden on health care systems. With fewer new antibiotics being developed, and the continuing emergence of new drug-resistant pathogens, ExThera’s sorbent hemoperfusion device should become an important new tool for critical care clinicians,” said Bob Ward, CEO, ExThera Medical.
BERKELEY, Calif.–(BUSINESS WIRE)–June 24, 2014–
ExThera Medical Corporation announced today that U.S. Patent No. 8,758,286 has been issued to the Company relating to its Seraph® Microbind® Affinity Blood Filter (Seraph). ExThera Medical also announced that it has listed an executive summary of its business at www.HealthiosXchange (H/X), an equity-based portal for accredited investors that raises funds under Rule 506 (b).
This key patent for ExThera Medical provides methods to engineer and manufacture ‘biomimetic’ devices that treat bloodstream infections quickly and safely. The main ingredient used to capture pathogens is heparin that is permanently bound to a substrate with high surface area.
“This is an important patent for ExThera, covering the therapeutic use of immobilized heparin in an extracorporeal device, to quickly remove dangerous bacteria, viruses, and toxins from whole blood. In addition, it covers the use of our ‘mixed media’ invention that combines the broad-spectrum binding of immobilized heparin with ‘supplemental adsorbents’, to remove even more pathogens and toxins, while retaining the desirable anticoagulant properties of the heparin surface,” said Bob Ward, CEO of ExThera Medical.
Seraph is designed to be the device equivalent of a very broad spectrum anti-infective drug, with the added benefit that bacteria removal by Seraph doesn’t release dangerous toxins into the patient’s bloodstream. In fact, when Seraph is used together with antibiotics, it may improve outcomes by scavenging the toxins released by pathogens killed by the drugs.
According to the World Health Organization (WHO), the world is heading for the post ‘anti-biotic era.’ Both the U.S. and Europe’s Centers for Disease Control (CDC) have released reports warning of the emergence of drug-resistance and the urgent need to address this global problem. So far little is being done. As an example, despite treatment with antibiotics, the reported mortality rate in patients with Carbapenem-Resistant Enterobacteriaceae (CRE) bloodstream infections is more than 50%.
ExThera has demonstrated in vitro efficacy of this patented technology by removing 5 different pathogens that are classified as ‘urgent’ or ‘serious’ by the US CDC. Additional in vitro studies have also shown efficient removal of many other bacteria, toxins, viruses, and fungi from blood. The Seraph Microbind Technology may be the only near-term solution to combat drug resistant infections.
“Once proven in upcoming clinical trials and approved for sale, Seraph has the potential to become a ‘blockbuster device’, based on the clinical need for preventing bloodstream infections from progressing to sepsis and septic shock. This is especially important when the infection is caused by drug-resistant bacteria like MRSA and ‘CRE Superbugs.’ No other therapy-drug or medical device-is designed to be as effective as Seraph® in removing a broad array of pathogens and toxins from the blood of bacteremic and viremic patients,” said Dr. Ward.
About HealthiosXchange (www.healthiosxchange.com)
HealthiosXchange (H/X) is an equity-based crowdfunding portal and broker/dealer that raises funds under Rule 506 (b). A member-only site, H/X offers private placements to Accredited investors. Some 2500 Accredited investors, emerging growth companies, investment professionals, and strategic buyers are registered members of H/X.
About ExThera Medical Corporation
Privately held ExThera Medical, based in Berkeley, Calif., is targeting the clinical treatment of blood-borne diseases including bacteremia, as well as the removal of harmful substances present in banked human blood. While medical treatments of bacteremia, e.g., caused by S. aureus or MRSA (Methicillin-Resistant S. aureus) usually rely on antibiotics, ExThera Medical’s Seraph® device capitalizes on the affinity of bacteria to attach to immobilized heparin within the device-a natural anticoagulant, that has many other biological attributes. Seraph® is designed to be a biomimetic adjunct to antibiotic therapy that reduces bacterial load and the duration of bacteremia, thereby potentially preventing complications such as endocarditis, osteomyelitis, and a systemic inflammatory response. The Company introduced its Seraph device concept to clinicians earlier this year at the annual congress of the Society for Critical Care Medicine.
CAUTION: ExThera Medical’s Seraph® device is not cleared by the FDA for distribution in the United States.
All information contained in this news release derives from plausible reliable sources, which, however, have not been independently examined. There is no warranty, confirmation or guarantee, and no responsibility or liability is taken concerning correctness or completeness. As far as it is allowed by the relevant law, no liability whatsoever is taken on for any direct or indirect loss caused by the deployment of this news release or its contents. This communication includes forward-looking statements regarding events, trends and business prospects that may affect our future operating results and financial position. Such statements are subject to risks and uncertainties that could cause our actual results and financial position to differ materially. The investment and/or the revenues that arise from it can rise or fall. A total loss is possible. Persons who are in possession of this news release are requested to obtain information concerning possible legal limitations and to observe them accordingly. We assume no responsibility to update or revise any forward-looking statements contained in this news release to reflect events, trends, or circumstances after the date of this news release.
Ronald Trahan A
Ronald Trahan, APR, +1-508-359-4005, x108
VB's research team is studying web-personalization... Chime in here, and we’ll share the results.